<DOC>
	<DOCNO>NCT01640964</DOCNO>
	<brief_summary>The main purpose exploratory study investigate effect serelaxin ( RLX030 ) infusion hepatic renal circulation patient compensate cirrhosis portal hypertension . Measurements acquire non-invasively use magnetic resonance angiography ( MRA ) ( study part A ) directly via cannulation hepatic portal vein routine transjugular intrahepatic portosystemic shunt ( TIPSS ) check procedure ( study part B ) , determine acute haemodynamic response serelaxin ( RLX030 ) .</brief_summary>
	<brief_title>An Exploratory Haemodynamic Study Patients With Compensated Cirrhosis Portal Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Study Parts A B : Cirrhosis alcohol aetiology accord physician 's assessment prior screening . Part A : Cirrhosis clinical and/or endoscopic evidence portal hypertension ( e.g . oesophageal varix ) . Part B : Cirrhosis TIPSS situ PPG &gt; 5mmHg . Fully function TIPSS without variceal filling confirm portography . Study Parts A B : Use drug treat portal hypertension ( e.g . vasodilator nonselective beta blocker nitrate ) within 1 month prior screen . Decompensated cirrhosis ( ChildPugh score &gt; 9 point , and/or ascites require diuretic , and/or hepatic encephalopathy ) visit 1 . Presence noncontrolled clinically significant disease could affect study outcome would place patient undue risk . Part A : BMI ( weight [ kg ] / height [ m^2 ] ) &gt; 40 kg/m^2 . Any contraindication MRI scan Part B : Contraindication catheterization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Portal hypertension , cirrhosis , TIPSS , MRI , MRA , portal pressure , portal pressure gradient</keyword>
</DOC>